Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.
Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW. Chakrabarti S, et al. Among authors: goldstone ah. Blood. 2002 Jun 15;99(12):4357-63. doi: 10.1182/blood.v99.12.4357. Blood. 2002. PMID: 12036862 Free article. Clinical Trial.
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S. Chakraverty R, et al. Among authors: goldstone ah. Blood. 2002 Feb 1;99(3):1071-8. doi: 10.1182/blood.v99.3.1071. Blood. 2002. PMID: 11807015 Free article. Clinical Trial.
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.
Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S, Chakraverty RK, Craddock C, Milligan DW, Pettengell R, Marsh JC, Linch DC, Goldstone AH, Williams CD, Mackinnon S. Branson K, et al. Among authors: goldstone ah. J Clin Oncol. 2002 Oct 1;20(19):4022-31. doi: 10.1200/JCO.2002.11.088. J Clin Oncol. 2002. PMID: 12351600
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
Pérez-Simón JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, García-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S; Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation. Pérez-Simón JA, et al. Among authors: goldstone ah. Blood. 2002 Nov 1;100(9):3121-7. doi: 10.1182/blood-2002-03-0701. Blood. 2002. PMID: 12384408 Free article.
Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.
Chakrabarti S, Avivi I, Mackinnon S, Ward K, Kottaridis PD, Osman H, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW. Chakrabarti S, et al. Among authors: goldstone ah. Br J Haematol. 2002 Dec;119(4):1125-32. doi: 10.1046/j.1365-2141.2002.03992.x. Br J Haematol. 2002. PMID: 12472597 Free article.
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications.
Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH, Mackinnon S, Hale G. Morris EC, et al. Among authors: goldstone ah. Blood. 2003 Jul 1;102(1):404-6. doi: 10.1182/blood-2002-09-2687. Epub 2003 Mar 6. Blood. 2003. PMID: 12623851 Free article. Clinical Trial.
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K. Peggs KS, et al. Among authors: goldstone ah. Biol Blood Marrow Transplant. 2003 Apr;9(4):257-65. doi: 10.1053/bbmt.2003.50009. Biol Blood Marrow Transplant. 2003. PMID: 12720218 Free article. Clinical Trial.
Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab.
Avivi I, Chakrabarti S, Milligan DW, Waldmann H, Hale G, Osman H, Ward KN, Fegan CD, Yong K, Goldstone AH, Linch DC, Mackinnon S. Avivi I, et al. Among authors: goldstone ah. Biol Blood Marrow Transplant. 2004 Mar;10(3):186-94. doi: 10.1016/j.bbmt.2003.11.001. Biol Blood Marrow Transplant. 2004. PMID: 14993884 Free article. Clinical Trial.
389 results